CANTARGIA AB
556791-6019ActiveDeveloping antibody-based drugs targeting IL1RAP for serious diseases.
Oversikt
- 20–49
- Ansatte
- ≤1t SEK
- Omsetning
- 2009
- Grunnlagt
Nøkkelbeslutningstakere
Hilde H. Steineger
CEO
Wolfram Dempke
Chief Medical Officer
Magnus Persson
Chairman of the Board
Damian Marron
Board Member
+6 flere kontakter i Funnelfeedr
Beskrivelse
Cantargia is a biotechnology company focused on developing innovative antibody-based therapeutics. Their primary scientific target is the protein IL1RAP, which plays a role in several serious conditions. The company's mission is to create treatments for cancer as well as autoimmune and inflammatory...
Tagger
Nøkkelord
Teknologier i bruk
Bedriftsinformasjon
- Bransje
- Annan naturvetenskaplig och teknisk forskning och utveckling
- Juridisk form
- Aktiebolag
- MVA-nummer
- SE556791601901
Beslutningstakere
10 kontakter i FunnelfeedrHilde H. Steineger
CEO
Wolfram Dempke
Chief Medical Officer
Magnus Persson
Chairman of the Board
Damian Marron
Board Member
Patrik Renblad
CFO
Flavia Borellini
Board Member
Ton Berkien
CBO
David Liberg
CSO
Jenny Sundqvist
Board Member
Anders Martin-Löf
Board Member
Lignende bedrifter
20 lignende bedrifter i FunnelfeedrHamlet BioPharma AB
5–9 ansatteInnovative pharmaceutical company developing targeted cancer and infection treatments.
Alligator Bioscience AB
10–19 ansatteClinical-stage biotech developing tumor-directed immuno-oncology antibody drugs.
Beactica Therapeutics AB
5 ansattePrecision medicine company developing novel therapeutics via targeted protein degradation.
BioGaia Pharma AB
0 ansatteDeveloping and out-licensing novel biotherapeutic platforms from microbiome research.
Nanohumps Biosciences Oy
Pioneering revolutionary cancer therapies using proprietary nanosized antibodies.
Utforsk mer
Spørsmål om CANTARGIA AB
Vil du se Funnelfeedr i aksjon?
Book en gratis demo og oppdag hvordan Funnelfeedr hjelper deg med å finne og konvertere dine ideelle kunder.
Book en demo